Indication: Multiple Myeloma
Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma
Patients with relapsed or refractory
Line of Therapy: 4th Line
Principal Investigator: Joseph Maly, M.D.Norton Cancer Institute
Sponsor: Regeneron Pharmaceuticals, Inc.
Email for more information: Heme-NCIResearch@nortonhealthcare.org